Myriad to present new research at the 2016 ASCO Annual Meeting

Myriad Genetics, Inc. (NASDAQ:MYGN) today announced it will present data from nine clinical studies with three different products at the 2016 American Society of Clinical Oncology annual meeting to be held June 3-7, 2016 in Chicago, Ill. Key podium presentations will highlight the safety and validity of the Myriad myRisk^® Hereditary Cancer multigene panel test in assessing hereditary cancer risk. Abstracts of the Company's presentations are available at: abstracts.asco.org.

"We're excited that the studies with myRisk Hereditary Cancer being presented at ASCO will advance the state-of-the-art of hereditary cancer testing," said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetic Laboratories. "In particular, our new data provide additional evidence for expanding testing to a broader set of patients at risk for developing hereditary cancers, and for understanding the risks associated with mutations."

Myriad's presentations are listed here. Follow Myriad on Twitter via @MyriadGenetics to stay informed about news and updates from the Company.

myRisk Hereditary Cancer Presentations
Podium Presentations